Context Therapeutics Management
Management criteria checks 3/4
Context Therapeutics' CEO is Martin Lehr, appointed in Jan 2015, has a tenure of 9.17 years. total yearly compensation is $1.06M, comprised of 45.1% salary and 54.9% bonuses, including company stock and options. directly owns 6.14% of the company’s shares, worth $1.35M. The average tenure of the management team and the board of directors is 2.6 years and 3 years respectively.
Key information
Martin Lehr
Chief executive officer
US$1.1m
Total compensation
CEO salary percentage | 45.1% |
CEO tenure | 9.2yrs |
CEO ownership | 6.1% |
Management average tenure | 2.6yrs |
Board average tenure | 3yrs |
Recent management updates
Recent updates
We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$24m |
Sep 30 2023 | n/a | n/a | -US$21m |
Jun 30 2023 | n/a | n/a | -US$19m |
Mar 31 2023 | n/a | n/a | -US$18m |
Dec 31 2022 | US$1m | US$477k | -US$15m |
Sep 30 2022 | n/a | n/a | -US$14m |
Jun 30 2022 | n/a | n/a | -US$12m |
Mar 31 2022 | n/a | n/a | -US$13m |
Dec 31 2021 | US$2m | US$291k | -US$10m |
Sep 30 2021 | n/a | n/a | -US$8m |
Jun 30 2021 | n/a | n/a | -US$7m |
Mar 31 2021 | n/a | n/a | -US$648k |
Dec 31 2020 | US$250k | US$250k | US$1m |
Dec 31 2019 | US$250k | US$250k | -US$6m |
Compensation vs Market: Martin's total compensation ($USD1.06M) is above average for companies of similar size in the US market ($USD662.11K).
Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.
CEO
Martin Lehr (39 yo)
9.2yrs
Tenure
US$1,057,653
Compensation
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. He was a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.2yrs | US$1.06m | 6.14% $ 1.4m | |
CFO & Treasurer | 2.3yrs | US$680.67k | 0.25% $ 55.3k | |
Chief Legal Officer & Corporate Secretary | 2.9yrs | US$653.10k | 0.39% $ 85.7k | |
Senior Vice President of Operations | 2.2yrs | no data | no data |
2.6yrs
Average Tenure
44yo
Average Age
Experienced Management: CNTX's management team is considered experienced (2.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 9.2yrs | US$1.06m | 6.14% $ 1.4m | |
Independent Chairman of the Board | 3yrs | US$149.20k | 0% $ 0 | |
Independent Director | 3yrs | US$97.31k | 0% $ 0 | |
Independent Director | 3yrs | US$100.81k | 0% $ 0 | |
Independent Director | 5.3yrs | US$80.81k | 0.022% $ 4.9k |
3.0yrs
Average Tenure
64yo
Average Age
Experienced Board: CNTX's board of directors are considered experienced (3 years average tenure).